The Cooper Companies, Inc. (COO) is a multinational corporation that operates through two business units: CooperVision and CooperSurgical. The company specializes in the development, manufacture, and sale of a range of specialty healthcare products.
CooperVision, the contact lens unit, is one of the world's leading manufacturers of soft contact lenses and related products and services. They develop, manufacture, and market a diverse range of contact lenses, including soft spherical lenses, soft toric lenses, soft multifocal lenses, and other premium contact lenses that are used to correct near- and farsightedness, as well as astigmatism and presbyopia. These products, known for their high quality and advanced technology, are distributed over 100 countries globally. CooperVision continuously invests in innovations and offers a wide selection of contact lenses to meet the unique visual requirements and lifestyle needs of customers worldwide.
On the other hand, CooperSurgical is focused on advancing the health of women, babies, and families with its diverse products and services for the women’s health care sector. The CooperSurgical business segment creates a wide array of medical devices, diagnostic products, and surgical instruments used primarily by obstetricians and gynecologists in their offices, clinics, hospitals, and surgical centers. The products by CooperSurgical range from fertility treatments to devices aiding in high-risk obstetric care which have contributed significantly to maternal and infant health worldwide.
The Cooper Companies, Inc., founded in 1980 and headquartered in San Ramon, California, has established a strong reputation for its commitment to quality, customer satisfaction, and continuous product development. Their innovative spirit, coupled with a focus on empowering people to enjoy a healthier and better life quality, has helped them carve a unique niche for themselves in their respective industries.
Despite a highly dynamic and challenging market environment, the Cooper Companies, Inc. has consistently demonstrated effective strategies, a broad product portfolio, extensive geographical reach, and a well-anchored customer relationship, which have helped to sustain their growth and profitability. The company's focus on meeting healthcare needs through innovative product solutions continues to inspire confidence among its stakeholders, tunneling its vision towards global leadership in improving lives, one person at a time.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends

MARKER THERAPEUTICS, INC. (MRKR) reported a Q3 loss of $0.1 per share, which was better than the Zacks Consensus Estimate of a $0.12 loss. However, the company missed revenue estimates, posting $1.29 million against a consensus of $2.45 million. The stock has underperformed the S&P 500 this year, and currently holds a Zacks Rank #3 (Hold).

Alcon's stock declined after the eye-care company narrowed its annual earnings outlook and reported weaker implantable-product sales, particularly due to US competitive pressure in intraocular lenses. Despite stronger quarterly earnings and cash generation, the durability of growth is being questioned, especially as a significant tariff refund artificially boosted operating income. Analysts expressed uncertainty regarding the company's growth trajectory without this one-off benefit.

The Rosen Law Firm is investigating potential securities claims against The Cooper Companies, Inc. (NASDAQ: COO) following a significant stock drop. This investigation comes after a September 10, 2026, article from The Motley Fool reported that Cooper Companies' stock fell by 14.6% due to disappointing earnings guidance and a decision not to sell CooperSurgical. The firm is encouraging investors who purchased Cooper Companies securities to inquire about joining a prospective class action lawsuit to recover losses.